Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma

BACKGROUND: Patients with high-risk stage II/III resected melanoma commonly develop distant metastases. At present, we cannot differentiate between patients who will recur or those who are cured by surgery. We investigated if circulating tumor DNA (ctDNA) can predict relapse and survival in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, R J, Gremel, G, Marshall, A, Myers, K A, Fisher, N, Dunn, J A, Dhomen, N, Corrie, P G, Middleton, M R, Lorigan, P, Marais, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834029/
https://www.ncbi.nlm.nih.gov/pubmed/29112704
http://dx.doi.org/10.1093/annonc/mdx717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834029/
https://www.ncbi.nlm.nih.gov/pubmed/29112704
http://dx.doi.org/10.1093/annonc/mdx717

Ejemplares similares